173 related articles for article (PubMed ID: 12170185)
1. Common prognostic factors for stage III melanoma patients and for stage I and II melanoma patients with recurrence to their regional lymph nodes.
Konstadoulakis MM; Messaris E; Zografos G; Ricaniadis N; Androulakis G; Karakousis C
Melanoma Res; 2002 Aug; 12(4):357-64. PubMed ID: 12170185
[TBL] [Abstract][Full Text] [Related]
2. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma.
Tas F; Erturk K
Int J Clin Oncol; 2019 Jun; 24(6):721-726. PubMed ID: 30788673
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis.
Glover AR; Allan CP; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
Br J Surg; 2014 Jun; 101(7):811-9. PubMed ID: 24752717
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
5. [Axillary recurrence after lymph node excision in malignant melanoma].
Kretschmer L; Lautenschläger C; Preusser KP; Fiedler H; Hetschko I
Langenbecks Arch Chir; 1993; 378(1):4-11. PubMed ID: 8437502
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis.
White RR; Stanley WE; Johnson JL; Tyler DS; Seigler HF
Ann Surg; 2002 Jun; 235(6):879-87. PubMed ID: 12035046
[TBL] [Abstract][Full Text] [Related]
7. Prognostic variables for patients with stage III malignant melanoma.
Messaris GE; Konstadoulakis MM; Ricaniadis N; Leandros E; Androulakis G; Karakousis PC
Eur J Surg; 2000 Mar; 166(3):233-9. PubMed ID: 10755339
[TBL] [Abstract][Full Text] [Related]
8. Number of Excised Lymph Nodes Has No Impact on Relapse and Survival in Patients With Stage III Melanoma.
Tas F; Erturk K
Ann Plast Surg; 2019 Oct; 83(4):455-458. PubMed ID: 31524742
[TBL] [Abstract][Full Text] [Related]
9. Treatment Outcome and Prognostic Factors for Malignant Skin Melanoma Treated with Radical Surgery.
Majewski W; Stanienda K; Wicherska K; Ulczok R; Wydmanski J
Asian Pac J Cancer Prev; 2015; 16(14):5709-14. PubMed ID: 26320440
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for nodal recurrence after lymphadenectomy for melanoma.
Pidhorecky I; Lee RJ; Proulx G; Kollmorgen DR; Jia C; Driscoll DL; Kraybill WG; Gibbs JF
Ann Surg Oncol; 2001 Mar; 8(2):109-15. PubMed ID: 11258774
[TBL] [Abstract][Full Text] [Related]
11. The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma.
Gipponi M; Solari N; Giovinazzo D; Queirolo P; Bertoglio S; Villa G; Gualco M; Bleidl D; Cafiero F
Anticancer Res; 2014 Jun; 34(6):3197-203. PubMed ID: 24922694
[TBL] [Abstract][Full Text] [Related]
12. Judging the therapeutic value of lymph node dissections for melanoma.
Chan AD; Essner R; Wanek LA; Morton DL
J Am Coll Surg; 2000 Jul; 191(1):16-22; discussion 22-3. PubMed ID: 10898179
[TBL] [Abstract][Full Text] [Related]
13. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
14. Elective lymph node dissection in stage I cutaneous malignant melanoma of the head and neck. A report from the Swedish Melanoma Study Group.
Hansson J; Ringborg U; Lagerlöf B; Afzelius LE; Augustsson I; Blomquist E; Boeryd B; Carlin E; Edström S; Eldh J
Melanoma Res; 1994 Dec; 4(6):407-11. PubMed ID: 7703722
[TBL] [Abstract][Full Text] [Related]
15. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy.
Lee RJ; Gibbs JF; Proulx GM; Kollmorgen DR; Jia C; Kraybill WG
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):467-74. PubMed ID: 10661355
[TBL] [Abstract][Full Text] [Related]
16. [Cutaneous malignant melanoma of the head and neck with intermediate tumor thickness: the role of elective lymph node dissection for clinical stage I].
Wenzel S; Sagowski C; Neuber K; Kehrl W; Metternich FU
Laryngorhinootologie; 2003 Jan; 82(1):19-24. PubMed ID: 12548460
[TBL] [Abstract][Full Text] [Related]
17. [Prognosis of malignant melanoma following dissection regional lymph node metastases].
Sprakel B; Stenschke F; Unnewehr M; Ladas A; Senninger N
Chirurg; 2003 Jan; 74(1):55-60. PubMed ID: 12552406
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of patients with pathologic stage II cutaneous malignant melanoma.
Roses DF; Provet JA; Harris MN; Gumport SL; Dubin N
Ann Surg; 1985 Jan; 201(1):103-7. PubMed ID: 3966826
[TBL] [Abstract][Full Text] [Related]
19. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN
Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814
[TBL] [Abstract][Full Text] [Related]
20. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
Fisher SR
Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]